Prof Richard Furie (New York, USA) and Dr Anastasia Madenidou evaluate the Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. They discuss the unique dose-response relationship endpoint used in this trial and the plans for Phase 3.Read the paper hereThanks for listening to Talking Rheumatology Research! Join the conversation on Twitter using #TalkingRheumResearch, or tweet us @RheumJnl. Want to read more of our research? Explore Rheumatology and Rheumatology Advances in Practice.